Previous 10 | Next 10 |
Encouraging early adoption of Trodelvy ™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key secondary endpoints of overall survival and objective response rate Full ASCEN...
Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...
AstraZeneca (NYSE: AZN) began the week with an eye-popping deal for a potential new cancer drug in a relatively early stage of development. The big pharma will hand its favorite collaboration partner, Daiichi Sankyo (OTC: DSNKY) , a whopping $1 billion upfront to develop and commercialize...
MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on...
A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a whole, stating that almost 70% of women diagnosed with triple-negative breast cancer (TNBC) do not receive care for their disease that is in accordance with guideli...
Immunomedics (NASDAQ: IMMU ) will extend its clinical collaboration with Roche ( OTCQX:RHHBY ) with two new clinical trials evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) and Tecentriq (atezolizumab) in bladder and lung cancer ...
Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant triple-negative breast cancer has begun patient enrollment MORRIS PLAINS, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Immunome...
( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...
Immunomedics Reports Positive Phase 3 Data for Cancer Drug Immunomedics Inc. ( IMMU ) reported that its confirmatory Phase 3 ASCENT study met its primary endpoint. The trial aimed to test Trodelvy for treating brain metastasis negative patients with mTNBC who have previously received at ...
Immunomedics (NASDAQ: IMMU ) announces positive results from a Phase 3 clinical trial, ASCENT , evaluating antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) in patients with relapsed/refractory triple-negative breast cancer (TNBC). More news on: Immunomedics, Inc., Hea...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...